Abstract
We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocarcinoma cells (PA-1) growing in three-dimensional tumour microspheroids (TMSs). Our study shows that PA-1 cells growing in TMSs are less susceptible to complement-mediated killing than cells growing in monolayer cultures, even after neutralization of protectin (CD59), the main inhibitor of complement lysis. Cells in suspension and cells growing in TMSs showed a similar expression of membrane co-factor protein (MCP, CD46) and CD59. Decay-accelerating factor (DAF, CD55) was not detected on the surface of cells in suspension, but appeared focally on the outermost cell layers of the TMSs. Complement-activating antibodies bound to all PA-1 cells in suspension but only to the most peripherally located cells in TMSs, even though the target antigens were similarly expressed in the two systems. Antibody-induced complement activation on PA-1 cells in suspension led to C3 and C5b-9 deposition on most cells, while C3 and C5b-9 were only found on the outermost layers of the TMSs. The increased complement resistance of tumour cells growing in three-dimensional spheroids is partly because of an insufficient penetration of antibodies and complement into the TMSs. TMSs are a useful model for the development of more efficient ways to kill malignant cells in micrometastases with monoclonal antibodies and complement.
Full text
PDF








Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bjørge L., Vedeler C. A., Ulvestad E., Matre R. Expression and function of CD59 on colonic adenocarcinoma cells. Eur J Immunol. 1994 Jul;24(7):1597–1603. doi: 10.1002/eji.1830240722. [DOI] [PubMed] [Google Scholar]
- Brackman D. Effects of 1,25-dihydroxyvitamin D3 on transformed C3H/10T1/2 fibroblasts grown as multicellular spheroids. Int J Cancer. 1995 Aug 9;62(4):428–435. doi: 10.1002/ijc.2910620412. [DOI] [PubMed] [Google Scholar]
- Brasoveanu L. I., Altomonte M., Gloghini A., Fonsatti E., Coral S., Gasparollo A., Montagner R., Cattarossi I., Simonelli C., Cattelan A. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. Int J Cancer. 1995 May 16;61(4):548–556. doi: 10.1002/ijc.2910610420. [DOI] [PubMed] [Google Scholar]
- Buckman R., McIlhinney R. A., Shepherd V., Patel S., Coombes R. C., Neville A. M. Elimination of carcinoma cells from human bone marrow. Lancet. 1982 Dec 25;2(8313):1428–1430. doi: 10.1016/s0140-6736(82)91329-0. [DOI] [PubMed] [Google Scholar]
- Cheung N. K., Walter E. I., Smith-Mensah W. H., Ratnoff W. D., Tykocinski M. L., Medof M. E. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest. 1988 Apr;81(4):1122–1128. doi: 10.1172/JCI113426. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fearon D. T. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5867–5871. doi: 10.1073/pnas.76.11.5867. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fletcher A., Bryant J. A., Gardner B., Judson P. A., Spring F. A., Parsons S. F., Mallinson G., Anstee D. J. New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes. Immunology. 1992 Mar;75(3):507–512. [PMC free article] [PubMed] [Google Scholar]
- Fletcher C. M., Harrison R. A., Lachmann P. J., Neuhaus D. Sequence-specific 1H-NMR assignments and folding topology of human CD59. Protein Sci. 1993 Dec;2(12):2015–2027. doi: 10.1002/pro.5560021203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fujimori K., Covell D. G., Fletcher J. E., Weinstein J. N. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res. 1989 Oct 15;49(20):5656–5663. [PubMed] [Google Scholar]
- Goodman G. E., Hellström I., Brodzinsky L., Nicaise C., Kulander B., Hummel D., Hellström K. E. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol. 1990 Jun;8(6):1083–1092. doi: 10.1200/JCO.1990.8.6.1083. [DOI] [PubMed] [Google Scholar]
- Guadagni F., Roselli M., Nieroda C., Dansky-Ullmann G., Schlom J., Greiner J. W. Biological response modifiers as adjuvants in monoclonal antibody-based treatment (review). In Vivo. 1993 Nov-Dec;7(6B):591–599. [PubMed] [Google Scholar]
- Hakulinen J., Meri S. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab Invest. 1994 Dec;71(6):820–827. [PubMed] [Google Scholar]
- Hamilton T. C., Ozols R. F., Longo D. L. Biologic therapy for the treatment of malignant common epithelial tumors of the ovary. Cancer. 1987 Oct 15;60(8 Suppl):2054–2063. doi: 10.1002/1097-0142(19901015)60:8+<2054::aid-cncr2820601518>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
- Heimer G. V., Taylor C. E. Improved mountant for immunofluorescence preparations. J Clin Pathol. 1974 Mar;27(3):254–256. doi: 10.1136/jcp.27.3.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Holmes C. H., Simpson K. L., Okada H., Okada N., Wainwright S. D., Purcell D. F., Houlihan J. M. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol. 1992 Jun;22(6):1579–1585. doi: 10.1002/eji.1830220635. [DOI] [PubMed] [Google Scholar]
- Houghton A. N., Mintzer D., Cordon-Cardo C., Welt S., Fliegel B., Vadhan S., Carswell E., Melamed M. R., Oettgen H. F., Old L. J. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A. 1985 Feb;82(4):1242–1246. doi: 10.1073/pnas.82.4.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jain R. K. Determinants of tumor blood flow: a review. Cancer Res. 1988 May 15;48(10):2641–2658. [PubMed] [Google Scholar]
- Jokiranta T. S., Meri S. Biotinylation of monoclonal antibodies prevents their ability to activate the classical pathway of complement. J Immunol. 1993 Aug 15;151(4):2124–2131. [PubMed] [Google Scholar]
- Junnikkala S., Hakulinen J., Meri S. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur J Immunol. 1994 Mar;24(3):611–615. doi: 10.1002/eji.1830240318. [DOI] [PubMed] [Google Scholar]
- Jäskeläinen J., Kalliomäki P., Paetau A., Timonen T. Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multi-cellular human glioma spheroids as targets. J Immunol. 1989 Feb 1;142(3):1036–1045. [PubMed] [Google Scholar]
- Langmuir V. K., Mendonca H. L., Woo D. V. Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids. Cancer Res. 1992 Sep 1;52(17):4728–4734. [PubMed] [Google Scholar]
- Meri S., Morgan B. P., Davies A., Daniels R. H., Olavesen M. G., Waldmann H., Lachmann P. J. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 1990 Sep;71(1):1–9. [PMC free article] [PubMed] [Google Scholar]
- Morgan B. P. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J. 1989 Nov 15;264(1):1–14. doi: 10.1042/bj2640001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Morgan B. P., Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol. 1994;15(4):369–396. doi: 10.1007/BF01837366. [DOI] [PubMed] [Google Scholar]
- Mueller-Klieser W. Multicellular spheroids. A review on cellular aggregates in cancer research. J Cancer Res Clin Oncol. 1987;113(2):101–122. doi: 10.1007/BF00391431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mäenpä A., Junnikkala S., Hakulinen J., Timonen T., Meri S. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol. 1996 Apr;148(4):1139–1152. [PMC free article] [PubMed] [Google Scholar]
- Ness G. O., Pedersen P. H., Bjerkvig R., Laerum O. D., Lillehaug J. R. Three-dimensional growth of glial cell lines affects growth factor and growth factor receptor mRNA levels. Exp Cell Res. 1994 Sep;214(1):433–436. doi: 10.1006/excr.1994.1277. [DOI] [PubMed] [Google Scholar]
- Nicholson-Weller A., Burge J., Fearon D. T., Weller P. F., Austen K. F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol. 1982 Jul;129(1):184–189. [PubMed] [Google Scholar]
- Pangburn M. K., Schreiber R. D., Müller-Eberhard H. J. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A. 1983 Sep;80(17):5430–5434. doi: 10.1073/pnas.80.17.5430. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reiter Y., Ciobotariu A., Fishelson Z. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Eur J Immunol. 1992 May;22(5):1207–1213. doi: 10.1002/eji.1830220515. [DOI] [PubMed] [Google Scholar]
- Riethmüller G., Johnson J. P. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. Curr Opin Immunol. 1992 Oct;4(5):647–655. doi: 10.1016/0952-7915(92)90041-c. [DOI] [PubMed] [Google Scholar]
- Riethmüller G., Schneider-Gädicke E., Johnson J. P. Monoclonal antibodies in cancer therapy. Curr Opin Immunol. 1993 Oct;5(5):732–739. doi: 10.1016/0952-7915(93)90129-g. [DOI] [PubMed] [Google Scholar]
- Rollins S. A., Sims P. J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol. 1990 May 1;144(9):3478–3483. [PubMed] [Google Scholar]
- Rubin S. C. Monoclonal antibodies in the management of ovarian cancer. A clinical perspective. Cancer. 1993 Feb 15;71(4 Suppl):1602–1612. doi: 10.1002/cncr.2820710427. [DOI] [PubMed] [Google Scholar]
- Seya T., Turner J. R., Atkinson J. P. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med. 1986 Apr 1;163(4):837–855. doi: 10.1084/jem.163.4.837. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stefanová I., Hilgert I., Kristofová H., Brown R., Low M. G., Horejsí V. Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. Mol Immunol. 1989 Feb;26(2):153–161. doi: 10.1016/0161-5890(89)90097-7. [DOI] [PubMed] [Google Scholar]
- Sugita Y., Nakano Y., Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem. 1988 Oct;104(4):633–637. doi: 10.1093/oxfordjournals.jbchem.a122524. [DOI] [PubMed] [Google Scholar]
- Sutherland R. M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 1988 Apr 8;240(4849):177–184. doi: 10.1126/science.2451290. [DOI] [PubMed] [Google Scholar]
- Thurnher M., Radmayr C., Ramoner R., Ebner S., Böck G., Klocker H., Romani N., Bartsch G. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer. 1996 Sep 27;68(1):1–7. doi: 10.1002/(SICI)1097-0215(19960927)68:1<1::AID-IJC1>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
- Zalman L. S., Wood L. M., Müller-Eberhard H. J. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6975–6979. doi: 10.1073/pnas.83.18.6975. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zeuthen J., Nørgaard J. O., Avner P., Fellous M., Wartiovaara J., Vaheri A., Rosén A., Giovanella B. C. Characterization of a human ovarian teratocarcinoma-derived cell line. Int J Cancer. 1980 Jan 15;25(1):19–32. doi: 10.1002/ijc.2910250104. [DOI] [PubMed] [Google Scholar]



